Jaw Osteonecrosis Tied to Treatment for Bone Metastases
MONDAY, Jan. 4, 2021 -- The cumulative three-year incidence of osteonecrosis of the jaw (ONJ) is 2.8 percent in cancer patients receiving zoledronic acid for metastatic bone disease (MBD), according to a study published online Dec. 17 in JAMA Oncology.
Catherine H. Van Poznak, M.D., from the University of Michigan in Ann Arbor, and colleagues examined the cumulative incidence of ONJ at three years in patients receiving zoledronic acid for MBD from any malignant neoplasm.
Among 2,263 participants with a baseline dental examination, the researchers found that 90 patients developed confirmed ONJ, with a cumulative incidence of 0.8 percent at year 1, 2.0 percent at year 2, and 2.8 percent at year 3. Among patients with myeloma, the three-year cumulative incidence was highest. ONJ was more likely among patients with planned zoledronic acid dosing intervals of less than five weeks versus those with planned dosing intervals of five weeks or longer (hazard ratio [HR], 4.65). A lower total number of teeth, the presence of dentures (HR, 1.83), and current smoking (HR, 2.12) were associated with a higher rate of ONJ.
"These data provide information to guide stratification of risk for developing ONJ in patients with MBD receiving zoledronic acid," the authors write.
© 2021 HealthDay. All rights reserved.
Posted: January 2021
Read this next
WEDNESDAY, Jan. 13, 2021 -- Several types of primary cancer are associated with an elevated risk for developing and dying from a subsequent primary cancer (SPC), according to a...
TUESDAY, Jan. 12, 2021 -- Overall cancer death rates have decreased continuously from 1991 to 2018, according to a study published online Jan. 12 in CA: A Cancer Journal for...
FRIDAY, Jan. 8, 2021 -- The Affordable Care Act (ACA) has reduced income inequality, with a larger decrease in states that expanded Medicaid, according to a study published in the...
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.